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After activation, Langerhans cells (LC), a distinct subpopulation of
epidermis-resident dendritic cells, migrate from skin to lymph
nodes where they regulate the magnitude and quality of immune
responses initiated by epicutaneously applied antigens. Modula-
tion of LC–keratinocyte adhesion is likely to be central to regula-
tion of LC migration. LC express high levels of epithelial cell
adhesion molecule (EpCAM; CD326), a cell-surface protein that is
characteristic of some epithelia and many carcinomas and that has
been implicated in intercellular adhesion and metastasis. To gain
insight into EpCAM function in a physiologic context in vivo, we
generated conditional knockout mice with EpCAM-deficient LC
and characterized them. Epidermis from these mice contained in-
creased numbers of LC with normal levels of MHC and costimula-
tory molecules and T-cell–stimulatory activity in vitro. Migration of
EpCAM-deficient LC from skin explants was inhibited, but chemo-
taxis of dissociated LC was not. Correspondingly, the ability of
contact allergen-stimulated, EpCAM-deficient LC to exit epidermis
in vivo was delayed, and strikingly fewer hapten-bearing LC sub-
sequently accumulated in lymph nodes. Attenuated migration of
EpCAM-deficient LC resulted in enhanced contact hypersensitivity
responses as previously described in LC-deficient mice. Intravital
microscopy revealed reduced translocation and dendrite motility
in EpCAM-deficient LC in vivo in contact allergen-treated mice.
These results conclusively link EpCAM expression to LC motility/
migration and LC migration to immune regulation. EpCAM appears
to promote LC migration from epidermis by decreasing LC–kerati-
nocyte adhesion and may modulate intercellular adhesion and cell
movement within in epithelia during development and carcino-
genesis in an analogous fashion.
Epidermal Langerhans cells (LC) are unique dendritic cells(DC) that are found in stratified squamous epithelia, in-
cluding skin. Features that distinguish LC from other DC include
morphologically distinct endocytic vesicles (termed “Birbeck
granules”) (1), an absolute dependence on TGF-β1 for devel-
opment (2), relative radio-resistance that reflects a life span of
months to years (3), and selective expression of several cell-
surface proteins that are anticipated to have important functions.
These proteins include Langerin (a C-type lectin) (4), E-cadherin
(an intercellular adhesion molecule) (5), and epithelial cell ad-
hesion molecule (EpCAM; CD326) (6) or its homolog TROP2
(TACSDT2) (7) in mice and humans, respectively. LC interca-
late among keratinocytes (KC), and this intimate relationship is
maintained as epithelial cells proliferate, differentiate, and are
shed. Although resting LC are relatively sessile, they regularly
extend and retract processes (dendrites) between KC, an activity
termed “dendrite surveillance extension and retraction cycling
habitude” (dSEARCH) (8) without disrupting epidermal in-
tegrity. LC movement within and emigration from epidermis is
increased after LC activation, as is dSEARCH activity. Vertical
projections of resting LC dendrites appear to be delimited by
epidermal tight junctions that form in the immediate subgranular
layer of the epidermis, whereas dendrites of activated LC can
penetrate tight junctions, facilitating uptake of antigens that are
present on skin surfaces (9).
Until recently, it was thought that LC were essential for ini-
tiation and propagation of effector T-cell responses directed
toward antigens that breached the outermost epidermal barrier
(the stratum corneum). Studies in mice that exhibit LC defi-
ciencies have changed this paradigm. Recent studies indicate
that LC do not function as essential antigen-presenting cells in
contact hypersensitivity reactions (10–12) or antiviral responses
(13, 14). Based on studies of contact hypersensitity (11, 15) and
cutaneous leishmaniasis (16), an immune-attenuating role for
LC has been suggested. However, additional studies suggest that
LC do promote the T-helper (Th) cell-selective effector responses
[e.g., Th2-predominant Ab responses after gene gun immuniza-
tion (17) and Th17 responses to fungus-associated antigens that
are encountered in skin (18)].
Functions of LC are predicated on the ability of LC to localize
and persist in epidermis and to traffic from skin to lymph nodes
(LN) in a carefully controlled fashion at baseline and after acti-
vation. Modulation of adhesion of LC to KC is likely to be central
to the regulation of LC trafficking, and mechanistic details re-
garding LC-KC adhesion remain to be elucidated. We previously
demonstrated that LC express E-cadherin (5), a homophilic ad-
hesion molecule that is an important component of adherens
junctions (19). It seems likely that LC trafficking is influenced by
changes in E-cadherin–dependent LC–KC adhesion (20–22), but
this concept has not been demonstrated formally.
EpCAM is another cell-surface protein that is expressed by LC
(6) and that might regulate LC trafficking. This transmembrane
glycoprotein is expressed in many developing epithelia (17, 23)
and in some epithelia (e.g., intestinal epithelia) in adult animals
(24). It has been suggested that EpCAM can promote in-
tercellular adhesion through homophilic interactions (25) but
also can attenuate cadherin-mediated adhesion (26). EpCAM
also has been studied intensively in the context of cancer, both
because, as a tumor antigen, it may represent a suitable target for
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immunotherapy (27) and because it may play a role in cancer
pathogenesis (28). EpCAM expression correlates with tumor
aggressiveness and poor prognosis and is linked to enhanced
cancer cell migration, invasion, and metastasis (29). More recent
studies have described a role for EpCAM in normal and cancer
stem function (30) and also suggested that EpCAM may be an
outside–in signaling molecule (31) that acts via a mechanism that
involves sequential proteolysis of EpCAM that is coupled to
regulation of transcription (31).
Most of what is known about EpCAM function is based on
studies of clonal transformed cells, and many reports emphasize
in vitro experiments. Conclusions drawn from such studies may
or may not be relevant to normal physiology (relating to LC or
other cells) or pathologic processes (such as cancer initiation and
progression) as they evolve in vivo. To begin to relate EpCAM
expression to LC function, several years ago we generated
EpCAM KO mice (32) using preexisting ES cells that carried
a targeted EpCAM allele that had been generated by gene
trapping (33). Although heterozygous EpCAM−/− mice did not
exhibit abnormalities, intercrossing these individuals failed to
yield viable EpCAM−/− animals because EpCAM−/− embryos
became nonviable at approximately embryonic day 12 secondary
to placental insufficiency (32). This mortality precluded studies
of LC and other lineages in postnatal EpCAM KO mice.
To circumvent the embryonic lethality associated with homo-
zygous EpCAM-null mutations, we engineered mice with floxed
EpCAM alleles that could be inactivated by introducing Cre
recombinase using a transgenic approach. Here we describe
conditional deletion of EpCAM in adult mice. For this initial
study, we generated mice with EpCAM-deficient LC and de-
termined that EpCAM that is expressed by LC regulates LC–KC
interactions and LC trafficking. These results increase our un-
derstanding of the significance of EpCAM expression by LC,
reiterate the importance of LC trafficking in LC function, and
also may relate to EpCAM function in normal epithelia and
cancer cells.
Fig. 1. Characterization of EpCAM-deficient LC in LC/EpCAM-cKO mice. (A) Demonstration in situ via immunofluorescence microscopy of EpCAM deletion in
LC in LC/EpCAM-cKO mice. Epidermal sheets from LC/EpCAM-cKO (KO) and Cre-negative (WT) animals were stained with anti-EpCAM and anti-MHC Class II
mAb and visualized using immunofluorescence microscopy (Scale bar: 50 μm.) Note residual EpCAM expression in hair follicles in WT and KO mice. (B)
Demonstration via flow cytometry of EpCAM deletion in LC in LC/EpCAM-cKO mice. Flow cytometric analysis of CD45+ MHC Class II+ Langerin+ cells (LC) and
CD45− MHC Class II− cells (KC) in epidermal cell suspensions from LC/EpCAM-cKO (KO) and WT animals. n = 3 mice per group in three experiments; thick line,
KO; thin line, WT; gray line with shading, isotype control. EpCAM expression levels are depicted as geometric mean fluorescence intensities (MFI). (C) Increases
in LC densities in LC/EpCAM-cKO mice. LC were enumerated by counting MHC Class II+ cells in epidermal sheets from KO and WT mice (five random fields per
mouse; n = 5 mice per group in six experiments.) *P < 0.005. DETC (TCR γ/δ-positive cells) were quantified in epidermal sheets from KO and WT mice (five
random fields per mouse, n = 3 mice per group in a single experiment). (D) T-cell–stimulatory activity of EpCAM-deficient LC. Epidermal cells from KO and WT
mice were cocultured with MHC-mismatched (BALB/c) naive T cells (n = 3 mice per group in three experiments using triplicate measurements in each ex-
periment). Numbers of LC per well were determined using flow cytometry to assess LC frequency in epidermal single-cell suspensions. T-cell proliferation was
measured by quantifying cleavage of WST-1 using a spectrophotometric assay.



























Generation and Characterization of Mice with EpCAM-Deficient LC.
We engineered mice with a floxed EpCAM allele that could be
conditionally inactivated (EpCAM-cKO mice) using recombin-
eering methodology (Fig. S1) (34). LoxP sites were inserted up-
stream and downstream of exons 1 and 2 of EpCAM in ES cells
using a targeting vector that contained a neomycin-resistance
gene flanked by FRT sites (Fig. S1A). Chimeric mice were gen-
erated using selected ES cells, germline transmission of the tar-
geted allele was established, and the neomycin-resistance marker
was deleted by crossing thesemice with transgenicmice expressing
Flp recombinase under control of the phosphoglycerate kinase 1
promoter [Flp deleter mice (35)] (Fig. S1 A–C). The mice that
resulted (EpCAMfl/fl or EpCAM-cKO mice) were indistinguish-
able fromunmanipulatedmice. Importantly, insertion of loxP sites
into the EpCAM locus did not influence expression of EpCAM by
LC or KC obtained from EpCAM-cKO mice (Fig. S1D).
EpCAM-cKO mice subsequently were crossed with huLan-
gerinCretg+ mice that selectively express Cre recombinase in
epidermal LC (11) to generate mice with EpCAM-deficient LC in
an otherwise WT background (LC/EpCAM-cKO mice) (see Fig.
S1A for a schematic representation of the anticipated recombined
EpCAM gene). Immunofluorescence staining of epidermal sheets
from WT and LC/EpCAM-cKO mice demonstrated virtually
complete deletion of EpCAM in MHC Class II+ epidermal cells
(LC) in LC/EpCAM-cKO animals with persistent low-level ex-
pression of EpCAM by some follicular KC (Fig. 1A). Flow cyto-
metric assessment of epidermal cell suspensions confirmed the in
situ staining results (Fig. 1B). Deletion of EpCAM in LC did not
result in cutaneous abnormalities that were evident by inspection
or by routine histology of trunk (Fig. S1E,Upper) or ear (Fig. S1E,
Lower) skin. Lineage-selective deletion of EpCAM was con-
firmed by assessing EpCAM expression in intestine. Immunoflu-
orescence staining of frozen sections of small intestine revealed
high levels of EpCAM on intestinal epithelial cells in both LC/
EpCAM-cKO and WT mice, as expected (Fig. S1F).
Phenotypic and Functional Characterization of EpCAM-Deficient LC.
Immunofluorescence images suggested that LC frequencies were
higher in LC/EpCAM-cKO epidermis than in controls. Enu-
meration of LC in epidermal sheets revealed that LC were ap-
proximately twofold more frequent in KO mice than in WT mice,
whereas dendritic epidermal T cells were represented similarly in
both strains (Fig. 1C). Flow cytometric studies of CD45+ MHC
Class II+ LC from unperturbed epidermis or from ear skin that
had been treated with 1% 2,4,6-trinitrochlorobenzene (TNCB)
18 h previously did not reveal differences between EpCAM-de-
ficient and control LC in the expression of MHC Class II, CD86,
CD40, or E-cadherin (Fig. S2A). Both EpCAM-deficient and
WT LC also up-regulated MHC Class II and costimulatory
molecules to similar extents during a 72-h culture period (Fig.
S2B), and the ability of WT and KO LC to stimulate pro-
liferation of naive allogeneic CD4 T cells was indistinguishable
(Fig. 1D). These results indicate that EpCAM is not required for
LC development or homing, LC activation or maturation, or LC
accessory cell activity as assessed by stimulation of naive T cells
in vitro.
EpCAM Is Required for Efficient Emigration of LC from Skin Explants.
The ability of LC to traffic from epidermis to regional LN is
thought to be critical for LC function. In addition, both in vitro
and in vivo studies previously have implicated EpCAM in in-
tercellular adhesion and/or migration (23, 26, 36). These data,
together with the increased numbers of steady-state LC in the
skin of LC/EpCAM-cKO mice, suggested that EpCAM might
regulate LC migration, an idea that we tested in vitro and in vivo.
Flotation of mouse ear skin explants on medium including the
chemokine CCL21 for 72 h revealed retention of EpCAM-de-
ficient MHC Class II+ Langerin+ LC in epidermis as compared
with WT LC, with a corresponding decrease in the accumulation
of EpCAM-deficient MHC Class II+ Langerin+ LC in cords
(representing lymphatics) (37, 38) in the dermis of explants (Fig.
2A). Enumeration of MHC Class II+ Langerin+ CD103− LC
that accumulated in the medium containing explants during a
72-h incubation revealed an approximately twofold decrease in
wells containing LC/EpCAM-cKO as compared with wells con-
taining WT skin (Fig. 2B). Fewer Langerin-expressing dermal
DC (dDC) (MHC Class II+ Langerin+ CD103+cells) than LC
emigrated from explants from mice of both genotypes, and
EpCAM expression did not influence Langerin+ dDC migration.
LC that migrated from WT and LC/EpCAM-cKO explants
expressed identical levels of the maturation markers MHC Class
II, CD86, and CD40 (Fig. S2C).
Fig. 2. Identification of a LC migration defect in skin explants from LC/EpCAM-cKO mice. (A) Retention of EpCAM-deficient LC in epidermis and paucity of
EpCAM-deficient LC in the dermis of explants. Epidermal and dermal sheets were prepared from ear skin from LC/EpCAM-cKO (KO) and WT animals after
flotation for 72 h on medium containing CCL21 (0.1 μg/mL) using ammonium thyiocyanate, stained with anti-Langerin and anti-MHC Class II mAb, and visu-
alized using immunofluorescence microscopy. (Scale bar: 50 μm.) (B) Selective decreases in the migration of EpCAM-deficient LC from skin explants. Ear skin
from KO andWT animals was floated on medium including CCL21 (0.1 μg/mL), and emigrated cells were counted after 72 h. White bars represent LC (MHC Class
II+ Langerin+, CD103− cells); black bars represent dDC (MHC Class II+, Langerin+, CD103+ cells). Data are from five experiments. n = 5 mice per group. *P < 0.001.








































To exclude a global requirement for EpCAM in LC motility or
chemokine-induced LC migration, we assessed the ability of
cultured LC to migrate in a 3D, dermis-like environment com-
prised of type I collagen toward a cytokine gradient in vitro in
real time (ref. 39 and Materials and Methods). In the absence of
CCL19, neither EpCAM-deficient nor control LC exhibited
significant directional migration over the 3-h observation period.
Introduction of chemokine induced migration of both LC/
EpCAM-cKO and WT LC. The directionalities and velocities of
chemokine-induced migration of EpCAM-deficient and control
LC could not be distinguished (Fig. 3 A and B and Movie S1),
indicating that EpCAM is not required for interstitial migration
of isolated LC in vitro.
Involvement of EpCAM in LC Migration in Vivo. To assess the in vivo
relevance of our in vitro findings, we studied the behavior of LC
in contact allergen-treated LC/EpCAM-cKO mice. Treatment of
WT and LC/EpCAM-cKO ear skin with 1% TNCB led to acti-
vation of significant subpopulations of LC (manifested by in-
creased MHC Class II and CD86 expression over baseline) 36 h
after TNCB treatment, as anticipated (Fig. 4A). In initial
experiments, the frequency of activated LC appeared to be higher
in LC/EpCAM-cKO mice than in WT mice 36 h after TNCB
exposure. Extension of these studies revealed that similar pro-
portions of activated LC (approximately 25%) were detected in
TNCB-treated KO and WT skin 18 h after hapten application
(Fig. 4B and Fig. S3). At the 36-h time point [and after emigra-
tion of activated LC from TNCB-treated epidermis had begun
(20)], the number of activated LC was approximataely twofold
higher in LC/EpCAM-cKO epidermis than in WT epidermis.
Differences between the number of activated LC in hapten-
treated KO and WT epidermis were not evident by 48 h after
TNCB treatment. These results suggest that EpCAM-deficient
LC are activated efficiently after application of TNCB to skin, but
their ability to exit epidermis after activation is attenuated.
We predicted that inhibition of the ability of EpCAM-deficient
LC to emigrate from contact allergen-treated epidermis would
result in delayed or reduced accumulation of hapten-bearing cells
in skin-draining LN. To test this hypothesis, we enumerated LC
in inguinal and axillary LN of WT and LC/EpCAM-cKO mice
before and after treatment of skin with TRITC in acetone:dibutyl
phthalate. Flow cytometry of skin-draining LN cells obtained 96 h
after TRITC painting revealed fewer TRITC+ CD11c+ MHC
Class IIhi DC in the LN of KOmice (5%) than in WTmice (18%)
(Fig. 4C). Enumeration of TRITC+ CD11c+ MHC ClassIIhi
Langerin+ CD103− CD11b+ cells in WT mice at various times
after TRITC treatment indicated that, as expected (12), numbers
of hapten-bearing LC that accumulated in LN were maximal 96 h
after TRITC treatment (Fig. 4D). Strikingly fewer TRITC+ LC
were isolated from LN of LC/EpCAM-cKO mice at each of the
time points examined, with only 25–30% of normal numbers re-
covered 96 and 120 h after hapten application (Fig. 4D).
Exaggeration of Contact Hypersensitivity Responses in LC/EpCAM-cKO
Mice. Studies of LC-deficient mice have resulted in new insights
into LC function. Several years ago, it was determined that mice
that were selectively deficient in epidermal LC exhibited exag-
gerated, prolonged responses to contact sensitizers (11). We pre-
dicted that LC/EpCAM-cKO mice might display a similar phe-
notype. Thus, WT and EpCAM-cKO mice were treated with 2,
4-dinitrofluorobenzene (DNFB) or vehicle and challenged with
DNFB on ear skin 5 d later. The ear-swelling responses that en-
suedweremore than twofold greater inKOmice than inWTmice,
and the duration of the response also was prolonged (Fig. 5).
These results recapitulate those seen in LC-deficient mice (11).
Characterization of LC Morphology and Motility in Situ. Our results
suggested that adhesion of LC and KC might be increased in the
absence of EpCAM. If so, increased adhesion could result in
morphologic changes in LC or in altered LC motility at baseline
or after activation. Confocal immunofluorescence microscopy of
LC in LC/EpCAM-cKO skin after staining with anti-MHC Class
II and anti–ZO-1 Ab (to delineate LC and tight junctions)
revealed that KO LC were larger and had longer, more delicate
dendrites than LC in WT skin (Fig. 6A and Movies S2 and S3).
These features were more obvious in skin that had been treated
with TNCB for 18 h (Movies S4 and S5) and in skin explants that
had been incubated for 72 h, in which WT LC retracted their
dendrites and adopted the polarized morphology typical of mi-
grating cells. EpCAM-deficient LC remained highly dendritic
and displayed a morphology that suggested arrested migration
(Fig. 6B). Assessment of the morphology of unperturbed LC
in the vertical (z) dimension indicated that in WT mice LC
dendrites abut but do not penetrate tight junctions that form
Fig. 3. Normal chemotaxis of EpCAM-deficient LC in collagen gels. (A)
Representative tracks of single LC migrating toward CCL19 within type I
collagen networks. Fifty LC of each genotype were tracked, and individual
tracks are displayed in a 2D graphic. The intersection of horizontal and vertical
lines represents the originating location for each cell at the beginning of the
observation period. (B) Quantification of LC chemotaxis in vitro. Velocities of
WT and EpCAM-deficient LC migrating toward CCL19 in collagen gels. Mi-
gration was measured over 3 h at 1-min intervals using 10× magnification (10
cells per field were tracked, five fields per group). Data depicted represent
mean velocities ± SEM of three experiments. No TX, no treatment.


























immediately below the granular layer in epidermis (Fig. 6C), as
previously reported (9). Interestingly, dendrites of EpCAM-de-
ficient LC appeared to terminate consistently at locations dis-
tinctively below that of tight junctions.
To determine if the motility of EpCAM-deficient LC was
compromised, we obtained dynamic images of LC in LC/EpCAM-
cKO and WT skin. LC/EpCAM-cKO and appropriate control
mice were crossed with EYFP reporter mice to generate corre-
sponding LC/EpCAM-cKO and WTmice that expressed EYFP in
LC (Materials and Methods). LC subsequently were imaged in vivo
in real time with a two-photon microscope at baseline (Movie S6)
and 18 h after treatment with TNCB (Movie S7). As expected (8),
translocation of LC within WT epidermis increased dramatically
after TNCB application (Fig. 7A). Although TNCB also increased
movement of EpCAM-deficient LC within epidermis, TNCB-
induced (but not basal) movement of these cells was inhibited by
approximately 80% (Fig. 7A). EpCAM deletion also altered
LC dSEARCH activity, a measure of LC dendrite motility (8).
Representative and aggregate data depicted in Fig. 7B show that
both basal and activation-associated dSEARCH activity was re-
duced dramatically in EpCAM-deficient LC. These results were
confirmed in limited studies involving mice whose LC expressed an
MHC Class II-EGFP fusion protein, in which LC dendrites could
be imaged in greater detail (Fig. 7C and Fig. S4A). Interestingly,
serial observation of MHC Class IIEGFP/+ LC/EpCAM-cKO LC
24 h after TNCB-induced activation revealed stationary dendrite
tips that appeared to be fixed in the upper epidermis, suggesting
enhanced LC–KC adhesion (Fig. 7D, Fig. S4B, and Movies S8
and S9). Occasionally dendrite tips remained fixed while associ-
ated LC bodies moved in the lower epidermis. This phenomenon
was not observed in WT LC. These observations of LC dynamics
suggest that loss of EpCAM impairs LC disengagement from KC,
potentially explaining the elongated LC morphology observed in
static images.
Discussion
During the past several years, it has become clear that murine
cutaneous DC are heterogeneous (17, 40, 41) and that identifi-
able DC subsets (including LC) have distinct functions (10–14,
16). Because EpCAM is one of the surface makers that are
useful for discriminating LC from other skin DC (6, 17), we were
interested in determining if EpCAM plays an important role in
LC physiology. Because EpCAMKOmice are nonviable (32), we
generatedmice with EpCAM-deficient LC by crossing EpCAMfl/fl
mice with huLangerinCretg+ mice to address this question.
huLangerinCretg+ mice express recombinase in LC but not in
other cells (including other Langerin-expressing DC). Thus, the
mice that we generated (LC/EpCAM-cKO mice) were expected
to have an LC-restricted defect in EpCAM expression.
Initial characterization revealed very efficient inhibition of
EpCAM expression by LC in LC/EpCAM-cKO mice. EpCAM
expression by KC and intestinal epithelial cells was not affected.
Characterization of isolated EpCAM-deficient LC did not reveal
abnormalities in cell-surface marker expression, maturation, ac-
cessory cell activity, or chemokine-induced migration. In con-
trast, studies of LC in vivo and skin explants uncovered several
differences between control and EpCAM-deficient LC. Although
EpCAM-deficient LC could be activated readily, their ability to
exit epidermis was attenuated, as reflected in a relative inability
of antigen-labeled EpCAM-deficient LC to migrate from epi-
dermis to regional LN, with a resulting increase in contact hy-
persensitivity. More detailed studies of LC behavior in vivo
suggested that loss of EpCAM expression resulted in increased
adhesiveness between LC and KC that led to the diminished
ability of activated LC to translocate within and out of epidermis
as well as to reductions in LC dSEARCH (8) at baseline and
after activation.
LC migration from epidermis to LN is a multistep process that
requires detachment of LC from KC; up-regulation of relevant
chemokine receptors and signaling that results in cytoskeletal
rearrangements enabling motility; production of enzymes that
mediate paracellular proteolysis that is required for passage of
cells through basement membranes and dermal connective tis-
sue; and expression of adhesion molecules that facilate entry into
and exit from lymphatic vessels and ultimately localization in the
LN paracortex. Previous reports involving KO mice have vali-
Fig. 4. Defective LC migration in LC/EpCAM-cKO mice in vivo. (A) Apparent retention of EpCAM-deficient LC in epidermis after TNCB application. Flow
cytometry of CD45+ MHC Class II+ Langerin+ cells in ear epidermal cell suspensions prepared 36 h after 1% TNCB painting revealed a subpopulation of MHC
Class IIhigh CD86high activated LC in situ (cells to the right of the vertical dashed line; thick line, KO; thin line, WT; gray line with shading, isotype control). (B)
Bar graph demonstrating transient retention of activated LC in ear epidermis of LC/EpCAM-cKO (KO) mice 36 h after TNCB painting. Data depicted represent
means ± SEM of two or three experiments. n = 3 mice per group. *P < 0.005. (C) Attenuated migration of EpCAM-deficient LC from epidermis to draining LN.
Abdominal skin of KO and WT animals was painted with 1% TRITC in dibutyl phthalate:acetone (1:1) or with vehicle, and single-cell suspensions were
prepared from skin-draining LN and were analyzed by flow cytometry. Dot plots reveal TRITC+ cells within live-gated CD11c+ cells after 96 h. (D) Reduced
absolute numbers of TRITC+ cells within live-gated CD11c+ MHC Class II+ Langerin+ CD103− CD11b+ cells (LC) in LC/EpCAM-cKO mice based on initial cell counts
from pooled skin-draining LN at 72, 96, and 120 h after TRITC painting. Data depict means ± SEM from three experiments. n = 3 mice per group. *P < 0.001.








































dated the importance of many of these events (42–52), but none
have focused on regulation of LC–KC adhesion, and only a few
have identified migration abnormalities that do not result from
motility defects (46, 47, 51). In addition, no previous studies used
mice with LC-restricted defects, and some of the results that
have been reported may relate to the behavior of Langerin-
expressing dDC in addition to, or even instead of, LC. Studies in
the model system that we describe here constitute definitive
proof that LC migration is required for LC function in vivo.
Because LC dendrite movement (dSEARCH) also is inhibited in
LC/EpCAM-cKO mice, it may be possible in future studies to
evaluate the physiologic significance of this activity.
The literature regarding EpCAM function in other cells is ex-
tensive (for review, see refs. 23 and 36), and it is not easy to
synthesize the variety of observations that have been reported into
a unified concept. Among the activities attributed to this protein,
it has been reported that EpCAM mediates adhesion (25), that it
reduces adhesion (26), and that it functions as a signaling mole-
cule (31). Because EpCAM is a molecule that interacts with
surrounding cells, it seems likely that context is important. For this
reason, in vivo studies of EpCAM function are of particular rele-
vance. To date, only a few studies have assessed endogenous
EpCAM function in vivo, and the studies that have been carried out
involve seemingly very different contexts [epithelial morphogenesis
in zebrafish (53), gastrulation in Xenopus (54), placental devel-
opment (32), and, in this report, LC migration in mice].
Although the contexts explored in these studies are varied,
several cross-cutting observations have been made. EpCAM
zebrafish mutants were identified in a screen for genes that
regulate skin development (53). EpCAM mutants and morphants
exhibited KC abnormalities that resulted in altered epithelial
morphogenesis and integrity. These defects were attributed to
altered adhesion between superficial and deeper layers of de-
veloping epidermis that resulted in morphologic abnormalities
[formation of extended apical junctional complexes (tight junc-
tions) and decreased formation of cellular protrusions] and de-
creased cell migration (epiboly) (53). It has been suggested that
EpCAM and E-cadherin are cooperative regulators of this pro-
cess, but mechanistic details remain to be determined. Depletion
of EpCAM in Xenopus embryos with morpholinos led to altered
gastrulation with ectodermal thickening, and overexpression of
EpCAM either in ectoderm or mesoderm caused abnormal cell
mixing (54). Structure–function studies indicated that the short
cytoplasmic tail that couples EpCAM to the cytoskeleton is both
necessary and sufficient to stimulate cell invasion. EpCAM also
was demonstrated to act by inhibiting the activity of an atypical
PKC that repressed cell mixing when active (54).
Our initial experiments in mice demonstrated that EpCAM−/−
embryos become nonviable because of placental insufficiency
resulting from attenuated development of the labyrinthine layer,
a process that involves invasion of fetal elements into the ma-
ternal decidua (32). When considered in conjunction with the
results of experiments reported here, the data accumulated from
studies of EpCAM function in vivo in physiologic contexts suggest
that EpCAM is an important regulator of movement of epithelial
cells of distinct lineages with respect to each other. Although not
yet formally demonstrated in any of these systems, it seems rea-
sonable to hypothesize that EpCAM functions as a modulator of
adhesion and that it acts by decreasing (rather than increasing)
intercellular adhesion. It is striking that EpCAM and classical
Fig. 5. Functional consequences of the migration defect in LC in LC/EpCAM-
cKO mice. Groups of five LC/EpCAM-cKO (KO) and Cre-negative littermate
control (WT) mice were sensitized with 0.5% DNFB on shaved abdomens on
day 0 and were challenged with 0.2% DNFB on ear skin on day 5. Negative
control WT mice (Vehicle) were sensitized with vehicle and also were chal-
lenged with 0.2% DNFB. (Upper) Data represent changes in thicknesses of
single ears over baseline at 24 h. (Lower) DNFB-induced ear swelling is shown
over 3 d in KO (thick line), WT (thin line), and vehicle-alone control mice
(thin broken line). Data represent means ± SEM from three experiments. n =
5 mice per group. *P < 0.001.
Fig. 6. High-resolution confocal immunfluorescence of LC in situ reveals
altered morphology in LC/EpCAM-cKO mice. (A) Epidermal sheets were
prepared from LC/EpCAM-cKO and WT mice at steady state, stained with
anti-MHC Class II mAb and anti-ZO-1 pAb, visualized using confocal mi-
croscopy, and are presented as 2D projections of z-volumes (WT, z = 35 μm;
KO, z = 30 μm). (Scale bar: 15 μm.) (B) Confocal images of intraepidermal LC
after incubation of skin explants with CCL21 (0.1 μg/mL) for 72 h and staining
with anti-MHC Class II mAb. (Scale bar: 10 μm.) (C) Composite en face images
and 90° rotation z-stacks of MHC Class II-expressing cells in epidermis at
steady state (Scale bar: 10 μm.)


























cadherins (especially E-cadherin) are coexpressed in tissues/cells
in which EpCAM has been shown to have physiologic roles, and
it has been reported previously that EpCAM can modulate
cadherin-mediated adhesion (26). At present, it is not clear if
EpCAM modulates cadherin function, and precise mechanisms
by which this modulation might be accomplished have not been
delineated. It also is not obvious that the outside–in signaling
activity that has been attributed to EpCAM (31) is linked to the
changes in cell behavior that have been observed in vivo.
EpCAM has been studied most extensively in cancer. Al-
though there are controversies, EpCAM may facilitate cancer
cell invasion and metastasis, and it has been suggested that
Fig. 7. Decreased LC motility in LC/EpCAM-cKO mice demonstrated via intravital microscopy. (A) Two-photon imaging was performed on ears of anes-
thetized LC/EpCAM-cKO (KO) and WT mice expressing EYFP in LC that were untreated (steady state) or were treated with 1% TNCB 18 h before imaging
(activated). Images were acquired every 2 min for 2.5 h, and 3D stacks (steady state, z = 11 μm; activated, z = 18 μm) were projected into 2D. (Left) LC positions
are represented with a red/green/blue color code with time 0 in blue, 1:15 h in green, and 2:30 h in red. (Scale bar: 10 μm.) (Right) Velocities of cell body
movements that were determined for approximately 50 cells per condition and analyzed with ImageJ using the Manual Tracking and Chemotaxis plugins.
*P < 0.01. (B) dSEARCH indices were determined in EYFP-expressing LC in WT and KO mice that had been treated with TCNB 18 h before analysis and were
compared with indices in untreated KO and WT mice. (Left) Aggregate dendrite position changes of 10 individual LC (indicated in different colors) per group
(measured at 12-min intervals over a 144-min observation period. (Right) Aggregate mean dSEARCH indices of 50 individual LC per group at steady state or 18
h after ears were painted with 1% TNCB (12-min intervals over 2.5 h). *P < 0.0001. Data represent means ± SEM. (C) Cell body displacement of MHC Class II-
EGFP–labeled LC 18 h after TNCB painting (z = 18 μm, projected into 2D). Color coding is as in A. (D) Immotile dendrite tips (arrows) of MHC Class II-EGFP–
expressing, EpCAM-deficient LC 24 h after TNCB painting (z = 18 μm, projected into 2D).








































EpCAM expression in tumors indicates poor prognosis (23, 29,
36). This viewpoint is attractive, because it is consistent with the
suggestion that EpCAM is a negative regulator of adhesion be-
tween epithelial cells. EpCAM expression by tumor cells might
promote detachment of tumor cells from normal epithelial cells
(or metastatic cells from malignant cells in primary tumors), just
as EpCAM may faciliate detachment of LC from KC before
movement from epithelia to LN. Elucidation of the signaling
pathways that are involved in regulation of intercellular adhesion
by EpCAM through studies of the conditional KO mice that we
have generated and strains that may be generated in the future
may lead to identification of new targets that are relevant for
development of cancer therapeutics and/or immunomodulators.
Materials and Methods
Mice.Mice generated at the National Cancer Institute are described below and
in SI Materials and Methods. huLangerinCretg+ mice were provided by Daniel
Kaplan (University of Minnesota, Minneapolis, MN). ROSA26 stopfl/flEYFP re-
porter mice (55) were purchased from Jackson Laboratories, and MHCIIEGFP/+
knockin reporter mice (56) were obtained from Taconic. All mice were bred
and housed in a pathogen-free environment and were used in experiments at
the National Institutes of Health in accordance with institutional guidelines.
Preparation of Epidermal Sheets and Single-Cell Suspensions. Epidermal
sheets, epidermal cell suspensions, and LN cell suspensions were prepared as
described in SI Materials and Methods.
Antibodies and Flow Cytometry. The antibodies used for these studies are
detailed in SI Materials and Methods. Data were collected with a LSRII flow
cytometer (BD) and analyzed with FlowJo software (Treestar). Nonviable
cells were excluded after 7-AAD (BD) staining, unless cells had been fixed
and permeabilized.
Mixed Epidermal Cell–Allogeneic T-Cell Reactions. Primary mixed epidermal
cell–allogeneic T-cell reactions were carried out as decribed in SI Materials
and Methods.
Assessment of LC Emigration Using Skin Explants. Skin explants were prepared
as previously described (37). Ears were divided into dorsal and ventral halves,
cartilage and s.c. tissue was removed, and skin was floated on RPMI medium
1640 (Invitrogen) containing 10% (vol/vol) heat-inactivated FBS (HyClone), 2
mM glutamine, 0.1 mM nonessential amino acids, 10 mM Hepes, 1% anti-
biotic/antimycotic (all from Invitrogen), 50 μM 2-mercaptoethanol (Sigma),
and 0.1 μg/mL CC chemokine ligand 21 (CCL21) (R&D Systems). Explants were
cultured for 72 h. DC that accumulated in the medium were enumerated
using Trypan blue (Invitrogen) and a hemocytometer (Neubauer) and were
characterized via flow cytometry. Absolute numbers of LC (MHC Class IIhigh
Langerin+ CD103−) and dDC (MHC Class IIhigh Langerin+ CD103+) that mi-
grated from explants were calculated. Epidermal and dermal sheets were
prepared from skin explants as described below.
Assessment of LC Chemotaxis in Vitro. LC chemotaxis in collagen gels was
assessed as previously described (39). Epidermal cell suspensions were cul-
tured in complete RPMI medium for 3 d, enriched for leukocytes using
Lympholyte-M density gradients (Cedarlane), added to soluble bovine col-
lagen type I (PureCol; Advanced BioMatrix) in Eagle’s minimal essential
medium at room temperature, and warmed to 37 °C after introduction into
specially prepared migration chambers (39). Polymerized gels were overlaid
with culture medium containing CCL19 (0.5 μg/mL), and cells were imaged
using a Zeiss AxioObserver Z1 inverted microscope equipped with a heated
stage, AxioVision (v.4.8) software, and either 10× (Plan-Apochromat N.A.
0.45) or 20× (Plan-Apochromat 0.8) objective lenses, with or without the
1.6× Optovar. Images of migrating LC were taken at 20-s intervals over 3-h
periods, and velocities were quantified with ImageJ software (National
Institues of Health) using the Manual Tracking and Chemotaxis tools.
Application of Haptens and Measurement of Contact Hypersensitivity Reac-
tions. LC activation in situ was achieved by applying 10 μL of 1% TNCB in
acetone:olive oil (4:1) to dorsal and ventral ear skin. Assessments were
performed at the indicated times. In some experiments, LC were activated
and labeled in situ using TRITC (Invitrogen) prepared as a 100-mg/mL (10%
wt/vol) stock solution in DMSO and diluted to 1% in acetone and dibutyl
phthalate (1:1) before application (100 μL) onto clipped abdominal skin.
Contact hypersensivity reactions to DNFB were elicited and quantified as
described in SI Materials and Methods.
Immunofluorescence Microscopy of Epidermal Sheets. Epidermal sheets were
prepared from ear skin and incubated in 3% (wt/vol) dry milk-PBS (Bio-Rad)
and 5 μg/mL rat anti-CD16/32 mAb (BD) for 1 h at room temperature to
minimize nonspecific staining before incubation with fluorochrome-labeled
mAb (5 μg/mL) for 1 h at room temperature or overnight at 4 °C. Conven-
tional immunofluorescence microscopy was performed using an AxioImager
A1 (Carl Zeiss Microimaging). Intensities of digital images in experimental and
control specimens were adjusted within the linear range with Zeiss Axiovison
software (all Carl Zeiss) and ImageJ. LC and dendritic epidermal T-cell (DETC)
densities were determined by counting five random fields per animal at 200×
final magnification. Confocal microscopy was performed with an inverted
LSM710 confocal microscope (Carl Zeiss Microimaging) equipped with a 63×/
NA 1.40 oil Plan-Apochromat objective using 0.3-μm optical slices. 3D image
stacks were reconstructed and animated with Imaris software (Bitplane).
Two-Photon Intravital Skin Imaging and Image Analysis. To visualize LC in
intravital studies, LC/EpCAM-cKO mice were crossed to Rosa26 stopfl/fl EYFP
mice, resulting in selective EYFP expression in LC, and to MHCIIEGFP/+ knockin
mice to achieve low EGFP expression in dDC and high EGFP expression in
mature LC. This third strain was used in a limited number of confirmatory
experiments and allowed visualization of LC dendrites with higher resolu-
tion. Two-photon intravital skin imaging was performed as previously de-
scribed (57). Mice were anesthetized using isoflurane (Baxter), and the
ventral sides of ear pinnae were fixed to coverslips at the bottom of the
imaging platform with tape strips. Images were acquired using an inverted
LSM 510 NLO multiphoton microscope (Carl Zeiss Microimaging) enclosed in
a custom environmental chamber with heated (32 °C) air. Images were ac-
quired using a 25×/0.8 NA Plan-Apochromat objective (Carl Zeiss Imaging)
with glycerol as the immersion medium. Fluorescence excitation was ac-
complished with a Chamelon XR Ti:Sapphire laser (Coherent) tuned to 920
nm for EGFP and to 940 nm for EYFP excitation. For 4D data sets, 3D stacks
were captured every 2 min.
Raw imaging data were processed with Imaris (Bitplane) using a Gaussian
filter for noise reduction. All images andmovies are displayed as 2Dmaximum
intensity projections unless otherwise stated. dSEARCH indices were calcu-
lated using an approach analogous to that of Nishibu and coworkers (8)
Briefly, position changes of all dendrite tips corresponding to individual LC
were tracked over the observation period, quantified using ImageJ and the
Manual Tracking and Chemotaxis plugins, and are expressed on a per cell
basis and as aggregated results for the numbers of LC indicated.
Statistical Analysis. Statistical significance was determined using Prism5 for
Mac (GraphPad Software). The Student’s t test was used after confirming
that all data fulfilled the criteria of normal distribution and equal variance.
P < 0.05 was considered statistically significant.
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Correction for “Cancer-associated epithelial cell adhesion mole-
cule (EpCAM; CD326) enables epidermal Langerhans cell motility
and migration in vivo,” by Maria R. Gaiser, Tim Lämmermann,
Xu Feng, Botond Z. Igyarto, Daniel H. Kaplan, Lino Tessarollo,
Ronald N. Germain, and Mark C. Udey, which appeared in issue
15, April 10, 2012, of Proc Natl Acad Sci USA (109:E889–E897;
first published March 12, 2012; 10.1073/pnas.1117674109).
The authors note that Fig. 1 and its corresponding legend ap-
peared incorrectly. The corrected figure and its corrected legend ap-
pear below. This error does not affect the conclusions of the article.
www.pnas.org/cgi/doi/10.1073/pnas.1604056113
Fig. 1. Characterization of EpCAM-deficient LC in LC/EpCAM-cKO mice. (A) Demonstration in situ via immunofluorescence microscopy of EpCAM deletion in
LC in LC/EpCAM-cKO mice. Epidermal sheets from LC/EpCAM-cKO (KO) and Cre-negative (WT) animals were stained with anti-EpCAM and anti-MHC Class II
mAb and visualized using immunofluorescence microscopy. (Scale bar: 50 μm.) Note residual EpCAM expression in hair follicles in WT and KO mice.
(B) Demonstration via flow cytometry of EpCAM deletion in LC in LC/EpCAM-cKO mice. Flow cytometric analysis of CD45+ MHC Class II+ Langerin+ cells (LC)
and CD45− MHC Class II− cells (KC) in epidermal cell suspensions from LC/EpCAM-cKO (KO) and WT animals. n = 3 mice per group in three experiments; thick
line, KO; WT, thin line, WT; gray line with shading, isotype control. EpCAM expression levels are depicted as geometric mean fluorescence intensities (MFI).
(C) LC densities in LC/EpCAM-cKO mice. LC were enumerated by counting MHC Class II+ cells in epidermal sheets from KO and WT mice (10 random fields per
mouse, 3–4 mice per group). Data presented are representative of three experiments. (D) T-cell–stimulatory activity of EpCAM-deficient LC. Epidermal cells
from KO andWT mice were cocultured with MHC-mismatched (BALB/c) naive T cells (n = 3 mice per group in three experiments using triplicate measurements
in each experiment). Numbers of LC per well were determined using flow cytometry to assess LC frequencies in epidermal single-cell suspensions. T-cell
proliferation was measured by quantifying cleavage of WST-1 using a spectrophotometric assay.
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